Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

TCGA-AO-A12G-01A-11R-A10J-07

— · A

9cec0387-9c3d-5935-95e9-0a7d98e3609a

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
A
subtype
A
overall_survival_months
55

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • OXIDATIVE_PHOSPHORYLATION+0.410
  • ANGIOGENESIS+0.400
  • PANCREAS_BETA_CELLS+0.390
  • BILE_ACID_METABOLISM+0.370
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.330
  • ADIPOGENESIS+0.310
  • COAGULATION+0.300
  • PEROXISOME+0.300
  • ANDROGEN_RESPONSE+0.290
  • CHOLESTEROL_HOMEOSTASIS+0.270

Top 10 suppressed

  • INTERFERON_ALPHA_RESPONSE-0.590
  • INTERFERON_GAMMA_RESPONSE-0.500
  • G2M_CHECKPOINT-0.360
  • TNFA_SIGNALING_VIA_NFKB-0.360
  • E2F_TARGETS-0.340
  • MITOTIC_SPINDLE-0.340
  • IL6_JAK_STAT3_SIGNALING-0.320
  • INFLAMMATORY_RESPONSE-0.260
  • ALLOGRAFT_REJECTION-0.220
  • COMPLEMENT-0.180

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1C3L-01632
lung-landscapes@6
—cohortA40.848
2SRR8518241
breast-umap@18
—F0.838
3SRR8518414
breast-umap@18
—C0.819
4SRR6013578
lung-landscapes@6
—cohortA20.803
5TCGA-AQ-A04L-01B-21R-A10J-07
breast-umap@18
—C0.794
6TCGA-A2-A0EM-01A-11R-A034-07
breast-umap@18
—B0.784
7TCGA-CV-6935-01A-11R-1915-07
head-neck@1
——0.779
8SRR1313101
breast-umap@18
—A0.777
9MBCProject_0755_T1_RNA
breast-umap@18
—B0.776
10TCGA-A2-A0EX-01A-21R-A034-07
breast-umap@18
—A0.774

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 32 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
OXIDATIVE_PHOSPHORYLATION0.410Remibrutinib— uncovered
ANGIOGENESIS0.400Remibrutinib— uncovered
PANCREAS_BETA_CELLS0.390Cobimetinib— uncovered
BILE_ACID_METABOLISM0.370Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.330Inavolisib— uncovered
ADIPOGENESIS0.310Inavolisib— uncovered
COAGULATION0.300Binimetinib— uncovered
PEROXISOME0.300Idelalisib— uncovered
ANDROGEN_RESPONSE0.290Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.270Remibrutinib— uncovered
FATTY_ACID_METABOLISM0.270Inavolisib— uncovered
XENOBIOTIC_METABOLISM0.220Inavolisib— uncovered
MYC_TARGETS_V20.210Idelalisib— uncovered
MYOGENESIS0.210Inavolisib— uncovered
ESTROGEN_RESPONSE_EARLY0.200Inavolisib— uncovered
GLYCOLYSIS0.200Inavolisib— uncovered
KRAS_SIGNALING_DN0.200Remibrutinib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.190Inavolisib— uncovered
PROTEIN_SECRETION0.180Remibrutinib— uncovered
MYC_TARGETS_V10.170Inavolisib— uncovered